Literature DB >> 33328706

Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy.

Evan D Lehrman1, Nicholas Fidelman1.   

Abstract

Neuroendocrine tumor liver metastases are treated by a multidisciplinary cohort of physicians that work together to achieve optimal clinical results for their patients. This review addresses critical concepts in diagnosis and workup of such patients followed by medical, surgical, and liver-directed arterial and ablative therapies. Specific perioperative care for these patients is crucial in avoiding dreaded complications related to Carcinoid Crisis. The recent introduction of Peptide Receptor Radionuclide Therapy as a therapeutic option has impacted some of the algorithms for timing and selection of arterial embolotherapies. Thieme. All rights reserved.

Entities:  

Keywords:  ablation; bland embolization; carcinoid crisis; chemoembolization; neuroendocrine tumor; peptide receptor radionuclide therapy; radioembolization

Year:  2020        PMID: 33328706      PMCID: PMC7732556          DOI: 10.1055/s-0040-1720951

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  37 in total

1.  THE CARCINOID CRISIS.

Authors:  M E KAHIL; H BROWN; H L FRED
Journal:  Arch Intern Med       Date:  1964-07

2.  Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.

Authors:  Daniel H Kwon; Alan Paciorek; Claire K Mulvey; Hilary Chan; Nicholas Fidelman; Lingzhong Meng; Eric K Nakakura; Li Zhang; Emily K Bergsland; Katherine Van Loon
Journal:  Pancreas       Date:  2019-04       Impact factor: 3.327

3.  Radioembolization-Induced Chronic Hepatotoxicity: A Single-Center Cohort Analysis.

Authors:  Brian M Currie; Maarouf A Hoteit; Edgar Ben-Josef; Gregory J Nadolski; Michael C Soulen
Journal:  J Vasc Interv Radiol       Date:  2019-07-26       Impact factor: 3.464

Review 4.  Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.

Authors:  Christophe M Deroose; Elif Hindié; Electron Kebebew; Bernard Goichot; Karel Pacak; David Taïeb; Alessio Imperiale
Journal:  J Nucl Med       Date:  2016-11-03       Impact factor: 10.057

5.  Risk factors for the development and progression of carcinoid heart disease.

Authors:  Sanjeev Bhattacharyya; Christos Toumpanakis; Deepika Chilkunda; Martyn Evan Caplin; Joseph Davar
Journal:  Am J Cardiol       Date:  2011-02-04       Impact factor: 2.778

6.  Case of carcinoid crisis following a fine-needle biopsy of hepatic metastasis.

Authors:  Vikram Sinha; Philip Dyer; Roy-Choudhury Shuvro; J Ian Geh; Sharad Karandikar
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-01       Impact factor: 2.566

7.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.

Authors:  T R Halfdanarson; K G Rabe; J Rubin; G M Petersen
Journal:  Ann Oncol       Date:  2008-05-30       Impact factor: 32.976

Review 8.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

9.  Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor.

Authors:  Johanna M Zuetenhorst; Johannes M G M Bonfrer; Catharina M Korse; Rob Bakker; Harm van Tinteren; Babs G Taal
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

10.  Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Aejaz Nasir; Pamela Hodul; Larry Kvols
Journal:  Gastrointest Cancer Res       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.